In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet

E-ISSN： 1532-6535|95|2|133-135

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.95, Iss.2, 2014-02, pp. : 133-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ITC Commentary on the Prediction of Digoxin Clinical Drug–Drug Interactions from In Vitro Transporter Assays

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 298-301

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 564-571

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 6, 2012-06 ,pp. : 1053-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1378-1385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 179-188

John Wiley & Sons Inc

Access to resources Recommend Favorite